Lone Star Funds

Lone Star Funds is a global private equity firm established in 1995, headquartered in Dallas, Texas, with additional offices across North America, Europe, and Asia. The firm operates as a value investor, specializing in identifying opportunities within complex or transitional situations, irrespective of the prevailing market environment. Its core mission involves unlocking value through a disciplined, flexible, and expert-driven approach, focusing on assets and cash flow rather than specific geographies or sectors.

Lone Star Funds' investment strategies encompass private equity, credit, and real estate. Within private equity, it targets corporate investments, financial institutions, and fulcrum corporate debt. Its credit strategy includes corporate credit and performing mortgage investments, while its real estate focus involves both debt and equity commercial real estate opportunities. The firm actively acquires distressed debt and equity assets, including corporate, commercial real estate, single-family residential, and consumer debt products, as well as banks and asset-rich operating companies. Since its inception, Lone Star has organized 26 private equity funds with aggregate capital commitments totaling approximately $96 billion.

In terms of leadership, John P. Grayken serves as the founder and Chairman, while Donald J. Quintin was appointed as the company's first Chief Executive Officer in April 2024. Recent activities include the April 2026 announcement of transformational dual acquisitions of RadiciGroup's High Performance Polymers and Specialty Chemicals Businesses and DOMO Engineered Materials, and the completion of the sale of novobanco to BPCE. In March 2026, Lone Star completed the acquisition of Alliance Ground International and announced the final closing of Residential Mortgage Fund IV. The firm also agreed to acquire the Capsules & Health Ingredients Division of Lonza Group AG in March 2026. In July 2024, Lone Star closed its latest opportunistic fund, Lone Star Fund XII, with $5.3 billion, earmarked for investments in companies affected by macroeconomic uncertainty and distressed corporate credits.